CA-GLOBALITY
4.5.2022 10:02:06 CEST | Business Wire | Press release
Aquanima Grupo Santander, a global procurement company that provides value solutions to Santander Group and other clients from different sectors around the world, has won the renowned AERCE El Diamante de la Compra® Award in the Innovation category for the way Santander is using Globality’s AI-powered Platform and Marketplace to transform how the bank sources B2B services.
The AERCE El Diamante de la Compra® Awards – organized by the Spanish Association of Purchasing, Contracting and Procurement Professionals (AERCE) – recognize outstanding work from procurement teams, and highlight the increasingly important function they play within their organizations, showcasing best practices and strategically valuable projects over the past 12 months.
The Innovation category recognizes a project, action or initiative that has demonstrated true innovation. The award is given to the procurement team that can demonstrate a radical new method or approach to one of the most challenging aspects of the sourcing process.
As a result of the partnership with Globality, Aquanima Grupo Santander is enjoying improved demand management and increased sourcing competition, and able to make more effective decisions, realize significant time and cost efficiencies, and foster greater collaboration between business stakeholders, procurement, and suppliers.
“We are delighted to receive this award, which is testament to our shared vision for the Future of Procurement,” said Jorge de la Vega, CEO of Aquanima. “That future, based on self-serve sourcing, is a competitive advantage for Aquanima Grupo Santander, helping us to continually evolve and boost our capabilities to give the best service to our clients.”
Aquanima’s project realized significant results within 90 days of adopting Globality’s Platform. In particular, Santander Bank realized substantial efficiencies by scoping their requirements in days instead of weeks, and awarding work in less than a month, drastically increasing speed to market and also saw average cost savings of 15% across projects awarded on the Platform.
“Globality is proud to partner with Aquanima Grupo Santander in revolutionizing the way Fortune 500 and Global 2000 companies buy services,” said Joel Hyatt, Chairman, Co-Founder and CEO, Globality. “For the first time, sophisticated, AI-powered technology exists to enable fair, competitive, sustainable self-serve sourcing for all indirect spend – unlocking a huge, new opportunity for procurement to create strategic business value and help meet the challenges of today’s volatile global economy.”
About Aquanima Grupo Santander
Aquanima Grupo Santander is a global procurement company with more than 20 years of experience that provides value solutions to Grupo Santander and other clients from different sectors around the world. Aquanima manages +10 billion per year, carries out more than 10,000 operations and homologates more than 5,000 suppliers.
Its expertise has been key for Grupo Santander to obtain the best efficiency ratio in the European financial industry. A knowledge that the company applies to the market in the 13 countries it’s placed, to +100 clients, thanks to the best team of +500 procurement experts.
Aquanima’s offer includes global solutions, both strategic and tactical that the company operates locally being adapted to each client needs in the sector and region in which they are located. All its solutions are applied under ESG criteria through its own TPRM model.
About Globality
Globality is a Silicon Valley-headquartered technology company co-founded by Joel Hyatt and Lior Delgo to connect global companies with the best suppliers at the right price for any sourcing need across every service category. Through its AI-powered Platform and Smart Sourcing technologies, Globality is bringing digital transformation to the sourcing industry. Globality’s AI digital solution replaces the archaic analog Request for Proposal, efficiently and effectively scoping needs, managing demand, matching companies with outstanding suppliers that meet their specific service needs, and cutting the sourcing process from months to hours while delivering savings of 20% or more. In January 2021, Globality raised $138 million from Sienna Capital and the SoftBank Vision Fund, bringing the total investment it has raised since its founding six years ago to $310 million. For more information, visit www.globality.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005494/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom